NIIMBL announces 32 projects funded as part of the US rescue plan



NEWARK, Del., 20 December 2021 / PRNewswire / – Today, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced 32 coronavirus response projects to multiple organizations across United States funded by the American Rescue Plan (ARP).

The NIIMBL has identified projects that will help the country prevent, prepare for, and respond to public health threats from coronaviruses. In addition, six of the projects establish research and development testbeds that will support collaborative research and innovation by the NIIMBL community at NIIMBL headquarters in Newark, DE.

“To overcome the current pandemic and prevent and prepare for future threats to public health, we must continue to build the necessary technology, infrastructure and skills,” said Kelvin lee, director of the institute. Lee adds, “This diverse group of technology and workforce development projects address multiple public health response capacities and strengthen United States’ role of world leader in biopharmaceutical manufacturing. ”

More specifically, thanks to ARP funding, NIIMBL has selected projects that:

  • Provide test beds for process development, for next-generation manufacturing approaches, and for pharmaceutical manufacturing approaches that provide access to industry-relevant equipment and facilities for pre-competitive manufacturing innovation
  • Support the development of significantly improved methods for the production, quality and distribution of vaccines, including mRNA and other vaccine platforms
  • Demonstrate rapid scale-up for the production of coronavirus antigens and medical countermeasures for variants of concern
  • Train a diverse workforce in the biopharmaceutical manufacturing industry
  • Demonstrate the concept of mobile good manufacturing practice capacities to support the production of mRNA vaccines and gene therapy

NIIMBL members include large and small businesses, academic institutions, nonprofit organizations, and federal agency partners who are well equipped to significantly strengthen the country’s preparedness and response to public health crises.

The list of funded projects and lead organizations includes:

Support pharmaceutical and bioproduction manufacturing with certificate in laboratory techniques to provide entry level workforce
Main organization: Cecil College

Preparing for and responding to a pandemic
Main organization: University of Missouri of science and technology

Establish test beds for the development of the biopharmaceutical manufacturing workforce
Lead organizations: Texas A&M University, University of Delaware, Central University of North Carolina, Xavier University of Louisiana, University of Maryland County of Baltimore

Evaluation of an automated vapor phase hydrogen peroxide decontamination system for rapid, non-residual decontamination of clinical spaces
Lead organization: Sentry Sciences LLC dba PMT (United States)

A new generation of high efficiency HVAC filters to stop the spread of the coronavirus
Main organization: North Carolina State University – The Non-woven Institute (NWI)

Rapid electrophoretic assay of mRNA vaccine quality attributes
Main organization: Carnegie Mellon University

Continuous purification for the production of mRNA vaccines: replacement of chromatography by adsorbent membranes
Main organization: Rensselaer Polytechnic Institute (RPI)

Rapid continuous production of room temperature stable mRNA vaccines
Lead Organizations: University of Massachusetts Lowell, Sepragen Corporation, University of Pennsylvania

Stability of the LNP-mRNA vaccine: reference materials, rapid assessment of stability and development of a lyophilized formulation
Lead organizations: Rensselaer Polytechnic Institute (RPI), Carnegie Mellon University

Advanced characterization and manufacture of mRNA vaccines
Main organization: Purdue University

Productivity and quality of mRNA vaccines
Main organization: North Carolina State University

Development of a vaccine against the heat-tolerant, multidose, egg-based, vector-based coronavirus
Lead organization: PATH

Accelerate the manufacture and scale-up of particulate viral vaccines
Main organization: Massachusetts Institute of Technology

Development of a CHO-based upstream process for the rapid production of coronavirus antigen variants
Lead organization: MilliporeSigma

Purification by affinity precipitation of viral-like particles
Main organization: University of Delaware

Spectro-Acoustic Process Analysis Technology for Continuous Coronavirus Vaccine Manufacturing
Lead organizations: Purdue University, Merck & Co.

Development of scalable, thermostable and spray-dried vaccine formulations applicable to coronavirus vaccines
Lead organizations: Fraunhofer United States, Merck & Co.

Heat-stabilized coronavirus vaccines: formulation and process development and rapid scale-up through QbD modeling and experimentation
Main organizations: Physical Sciences Inc., University of Connecticut, University of Massachusetts Lowell, Merck & Co.

Development of internal SARS-CoV-2 NGS standards to ensure sufficient complexity capture for variant detection and diagnosis
Lead organization: Accugenomics Inc.

Single-use rapid nucleic acid test based on PCR
Main organization: Texas A&M University

A bioelectronic sensor for rapid assessment of antibody titer and glycan structure
Main organization: University of Maryland, College Park

Non-invasive detection of counterfeit and substandard vaccines and biotherapeutics
Main organization: University of Maryland, Baltimore

Cutting-edge identification nanobodies panel for the manufacture of SARS-CoV-2 vaccines
Lead organizations: Wadsworth Center, New York State Department of Health, University of Massachusetts School of Medicine

Manufacture of open source lentiviral vectors and viral vectors associated with adenoviruses
Main organization: Caring Cross

Expression of monoclonal antibodies in rapid alternative hosts: demonstration and reference material
Main organization: Massachusetts Institute of Technology

Production of NIIMBL antibodies in C1 expression systems of Thermothelomyces heterothallica
Main organization: Dyadic

Improved end-to-end manufacturing test bed for fast and flexible drug manufacturing
Main organization: NIIMBL

Next Generation Sequencing Test Bench
Main organization: NIIMBL

Portable GMP plasmid production test bench
Main organization: NIIMBL

NIIMBL Vaccine Analytics and Assays Center of Excellence
Main organization: NIIMBL

Process development test bench
Main organization: NIIMBL

BPF type pharmaceutical test bench laboratory
Main organization: NIIMBL

Visit to see a summary of these projects and learn more about NIIMBL.


The National Institute for Innovation in the Manufacturing of Biopharmaceuticals (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, to support the development of standards that enable more efficient manufacturing capabilities. and faster, and to educate and train a leading biopharmaceutical manufacturing workforce. , fundamentally advancing the competitiveness of the United States in this industry. NIIMBL is part of Manufacturing United States®, a diverse network of federally sponsored manufacturing innovation institutes, and is funded by a cooperative agreement with the National Institute of Standards and Technology (NIST) of the United States Department of Commerce with significant additional support from its members .

Maria x chacon
Marketing and communications director
[email protected]

SOURCE National Institute for Innovation in the Manufacturing of Biopharmaceuticals (NIIMBL)



Comments are closed.